FDA Subcutaneous Injection Site Simulator (SCISSOR)
Key Dates
Due Date
-
Posted Date
-
Agency & Value
Agency
FDA OFFICE OF ACQ GRANT SVCS
Contract Value
Not provided
Codes & Classification
Solicitation Number
75F40126Q134239
NAICS
334516 - Analytical Laboratory Instrument Manufacturing
Classification Code
6640
Additional Details
Documents2
The U.S. Food and Drug Administration (FDA), through its Office of Acquisition and Grant Services, has issued a solicitation for the procurement of a Subcutaneous Injection Site Simulator (SCISSOR) to support the Division of Pharmaceutical Quality Research V (DPQRV). This initiative is aimed at enhancing the FDA’s research capabilities in pharmaceutical quality by acquiring advanced simulation equipment that replicates subcutaneous injection sites. The primary objective is to facilitate more accurate and reliable testing, training, and evaluation related to subcutaneous drug delivery, ultimately contributing to improved regulatory science and public health outcomes.
The scope of this procurement encompasses the acquisition of a specialized analytical laboratory instrument, as classified under NAICS code 334516 (Analytical Laboratory Instrument Manufacturing). The selected solution must meet the technical and functional requirements detailed in the solicitation documents, which are available as attached PDF files referenced in the notice. Contractors are expected to provide a simulator that aligns with the FDA’s stringent standards for research instrumentation, ensuring high fidelity, durability, and compatibility with the agency’s existing research protocols.
Key deliverables for this contract include the delivery, installation, and potential training or support services associated with the SCISSOR system. The FDA anticipates that the simulator will be used extensively in laboratory settings to model and analyze subcutaneous injection scenarios, supporting both current and future research initiatives within the DPQRV.
This opportunity is set aside for small businesses, as indicated by the SBA set-aside designation, encouraging participation from qualified small business manufacturers and suppliers within the United States. The place of performance is within the United States, and all work and deliverables are expected to comply with federal standards and regulations.
The contracting entity for this solicitation is the FDA Office of Acquisition and Grant Services, operating under the Department of Health and Human Services. Interested parties should direct all inquiries and submissions to the primary point of contact, Tim Walbert, who can be reached via email at [email protected] or by phone at 301-796-1768.
The solicitation is currently active, with a response deadline extended to August 5, 2026, at 2:00 pm CDT, as noted in Amendment 01. Prospective contractors are encouraged to review all attached documentation thoroughly to ensure compliance with submission requirements and to assess alignment with their organizational capabilities.
For further details and access to the solicitation documents, interested vendors should refer to the official notice on SAM.gov using Opportunity ID bf716d93ce7c4dd380f4c21fcd06f256 or visit the provided URL: https://sam.gov/opp/bf716d93ce7c4dd380f4c21fcd06f256/view.